ConductScience.org, home

Comparison · NCT00566345-07e0ff93

Influenza Vaccine vs Placebo: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Influenza Vaccine vs Placebo: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens. Trial comparisons, record NCT00566345-07e0ff93. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00566345-07e0ff93

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01950.01410.027wilson
Risk in group 20.03410.02670.0435wilson
Risk difference, group 1 minus group 2-0.0146-0.0254-0.00404newcombe hybrid score
Risk ratio, group 1 over group 20.5720.380.862log
Odds ratio, group 1 over group 20.5640.3710.858log
Number needed to treat, for one fewer participant with the outcome on Influenza Vaccine than on Placebo68.539.3248from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Influenza VaccineVero-cell derived influenza vaccine~Inactivated seasonal influenza vaccine (split virus, Vero cell-derived): Trivalent, non-adjuvanted vaccine; dose: 0.5 ml351,792OG000
Group 2Placebo
Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)~Phosphate buffered saline: Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
621,817OG001

Outcome

Type
PRIMARY
Title
Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens
Description
Time frame
21 days to 180 days after the date of vaccination
Population
Intent-to-Treat

Source ClinicalTrials.gov

Trial

Title
Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
NCT number
NCT00566345
Phases
PHASE3
Conditions
Influenza
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
Lead sponsor
Alachua Government Services, Inc.
Results first posted
2023-10-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00566345-07e0ff93